Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics
出版年份 2020 全文链接
标题
Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics
作者
关键词
-
出版物
Frontiers in Oncology
Volume 10, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2020-11-17
DOI
10.3389/fonc.2020.561936
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The antipsychotic chlorpromazine suppresses YAP signaling, stemness properties, and drug resistance in breast cancer cells
- (2019) Chang-En Yang et al. CHEMICO-BIOLOGICAL INTERACTIONS
- 1478OResults of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain
- (2019) L Q Chow et al. ANNALS OF ONCOLOGY
- 1570PPioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non-small cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)
- (2019) D Heudobler et al. ANNALS OF ONCOLOGY
- Design, synthesis and evaluation of novel phenothiazine derivatives as inhibitors of breast cancer stem cells
- (2019) Yuan Gao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The Rationale for Repurposing Sildenafil for Lung Cancer Treatment
- (2018) Theodore Keats et al. Anti-Cancer Agents in Medicinal Chemistry
- Clonal Hematopoiesis after Induction Chemotherapy for Acute Myeloid Leukemia
- (2018) David P. Steensma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells
- (2018) Amila K. Nanayakkara et al. Scientific Reports
- Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors
- (2018) Suresh K. Agarwal et al. ADVANCES IN THERAPY
- Sertraline, chlorprothixene, and chlorpromazine characteristically interact with the REST-binding site of the corepressor mSin3, showing medulloblastoma cell growth inhibitory activities
- (2018) Jun-ichi Kurita et al. Scientific Reports
- Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies
- (2017) Ranjeet Prasad Dash et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit
- (2017) Claudia R. Oliva et al. Oncotarget
- Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer
- (2017) Kalliopi Domvri et al. Journal of Cancer
- Exploring the Role of CYP3A4 Mediated Drug Metabolism in the Pharmacological Modulation of Nitric Oxide Production
- (2017) José Pérez-del Palacio et al. Frontiers in Pharmacology
- Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine
- (2016) Dolly A. Parasrampuria et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis
- (2016) Mona El-Naa et al. Drug Design Development and Therapy
- Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors
- (2015) Elizabeth Fox et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1
- (2015) Wen-Ying Lee et al. Oncotarget
- PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells
- (2014) Jane L Roberts et al. CANCER BIOLOGY & THERAPY
- Interaction of 11C-Tariquidar and 11C-Elacridar with P-Glycoprotein and Breast Cancer Resistance Protein at the Human Blood-Brain Barrier
- (2013) M. Bauer et al. JOURNAL OF NUCLEAR MEDICINE
- Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
- (2012) A. Palmeira et al. CURRENT MEDICINAL CHEMISTRY
- Pgp-Mediated Interaction Between (R)-[11C]Verapamil and Tariquidar at the Human Blood–Brain Barrier: A Comparison With Rat Data
- (2011) M Bauer et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Synthesis and evaluation of [11C]XR9576 to assess the function of drug efflux transporters using PET
- (2010) Kazunori Kawamura et al. ANNALS OF NUCLEAR MEDICINE
- Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor
- (2010) Florian Bauer et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Dismounting the MDR horse
- (2010) E. Libby et al. BLOOD
- Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999
- (2010) L. D. Cripe et al. BLOOD
- A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
- (2010) R. J. Kelly et al. CLINICAL CANCER RESEARCH
- Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays
- (2010) Vesna Munić et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine
- (2009) J. Abraham et al. CLINICAL CANCER RESEARCH
- Phase III Study of Valspodar (PSC 833) Combined With Paclitaxel and Carboplatin Compared With Paclitaxel and Carboplatin Alone in Patients With Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary Peritoneal Cancer
- (2008) Catherine Lhommé et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia
- (2008) Jeffrey E. Lancet et al. LEUKEMIA RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started